October 29, 2025 — Leads & Copy — Guardant Health, Inc. (Nasdaq: GH) reported its Q3 2025 financial results, with total revenue reaching $265.2 million, a 39% increase year-over-year. Oncology revenue increased by 31% to $184.4 million, and screening revenue was $24.1 million, driven by Shield tests. The company expects full-year 2025 revenue to be between $965 to $970 million.
The company achieved several operating milestones, including expanding Shield to include multi-cancer detection, establishing strategic collaborations with Quest Diagnostics and PathGroup, and submitting the Guardant360 Liquid PMA application to the FDA. Guardant Health now expects full-year 2025 revenue to be in the range of $965 to $970 million, representing growth of approximately 31% compared to full-year 2024.
“This was an exceptional quarter for Guardant with broad-based growth across our business,” said Helmy Eltoukhy, co-founder and co-CEO. AmirAli Talasaz, co-founder and co-CEO, added, “We made incredible progress in Screening in the third quarter. It has been very rewarding to see Shield take off and hear story after story of patients positively impacted by this pioneering test.”
Guardant Health is a precision oncology company transforming patient care and accelerating new cancer therapies through its advanced blood and tissue tests, real-world data, and AI analytics.
Contact:
Guardant Health Investor Relations
investors@guardanthealth.com
+1 650-900-2200
Source: Guardant Health, Inc.
